Alkermes plc - Ordinary Shares (NQ:ALKS)

45.15 -0.22 (-0.50%)

Delayed Quote Updated: 10:27 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

A Better Switch ↗

June 04, 2021

Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase.

Via Talk Markets

The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award

May 17, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Supports Mental Health Clinical Research

April 26, 2021

SOURCE: Alkermes

Via 3BL Media

Are You Thinking About Your Alcohol Drinking Habits?

April 23, 2021

SOURCE: Alkermes

Via 3BL Media

"I'm Incredibly Proud to Work at a Company Whose Mission Is To Help Families Like Mine"

June 02, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med ↗

June 01, 2021

The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic...

Via Benzinga

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

Alkermes Celebrates World Health Day 2021

April 07, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Inspiration Grants® 2021 Applications Are Now Open

May 24, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Celebrates Mental Health Month

May 19, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

May 13, 2021

SOURCE: Alkermes

Via 3BL Media

Why Shares of Alkermes Rose 18% Last Month ↗

May 07, 2021

An agreement with an activist investor capped a busy month.

Via The Motley Fool

Want to Make Money in Biotech? Do This First ↗

May 07, 2021

Keeping track of upcoming events is important.

Via The Motley Fool

Topics Regulatory Compliance

Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month

May 04, 2021

SOURCE: Alkermes

Via 3BL Media

Topics Regulatory Compliance

The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs ↗

April 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...

Via Benzinga

Alkermes PLC (ALKS) Q1 2021 Earnings Call Transcript ↗

April 29, 2021

ALKS earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence

April 29, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes: Q1 Earnings Insights ↗

April 28, 2021

Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11,...

Via Benzinga

The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping ↗

April 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc...

Via Benzinga

Alkermes Launches Mid-Stage Melanoma Study Of Nemvaleukin As Monotherapy ↗

April 27, 2021

Alkermes plc (NASDAQ: ALKS) has initiated a Phase 2 trial, ARTISTRY-6, evaluating nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma...

Via Benzinga

The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗

April 24, 2021

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...

Via Benzinga

Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society

April 22, 2021

SOURCE: Alkermes

Via 3BL Media

Topics Regulatory Compliance

This Alcohol Awareness Month, Reevaluate Your Relationship With Alcohol

April 16, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Shares Immuno Oncology Clinical Trial Research

April 15, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Celebrates National Minority Health Month

April 14, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Provides Resources for Talking to a Loved One About Alcohol Dependence

April 12, 2021

SOURCE: Alkermes

Via 3BL Media

How Posting About Alcohol May Be Hurting Those Having Trouble Coping With the Pandemic

April 08, 2021

SOURCE: Alkermes

Via 3BL Media

The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award ↗

April 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Topics Intellectual Property

Alkermes Employee Reflects on His Family's Experience with Cancer and How It Impacts His Work

April 06, 2021

SOURCE: Alkermes

Via 3BL Media

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.